Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains

J Beltman, DE Becker, E Butt, GS Jensen, SD Rybalkin, B Jastorff and JA Beavo

Department of Pharmacology, University of Washington, Seattle 98195.

To help define essential interactions of cGMP with the catalytic site, we tested a series of cGMP analogs as competitive inhibitors of each cyclic nucleotide phosphodiesterase (PDE) family known to hydrolyze cGMP (PDE1, PDE2, PDE3, PDE5, and PDE6). IC50 values, relative to cGMP, were used to predict which functional groups of cGMP contribute to binding by the catalytic sites of each isozyme. The results indicate that the N1-nitrogen of cGMP contributes to binding at the catalytic site of all PDEs, probably as a hydrogen donor. All PDEs tested, with the exception of PDE2, also use the 6-oxo group, probably as a hydrogen acceptor. In contrast to other cGMP-binding enzymes, the 2-amino and 2'- hydroxyl groups of cGMP are not major requirements for binding to any PDE. The 8-bromo- and 8-p-chlorophenylthio-substituted analogs inhibit PDE1, PDE2, and PDE6 activity with high relative affinities, suggesting that these PDEs are not sterically hindered with bulky 8-position substitutions and that they do not preferentially bind the anti- conformation of cGMP. PDE3 and PDE5 have reduced apparent affinity for these analogs and therefore either are sterically hindered with these substitutions or bind cGMP in the anti-conformation. Overall, the data show substantial differences in structural requirements for cGMP binding to the catalytic sites of the different PDE families. Comparisons with published data show different structural requirements for binding to the catalytic, compared with noncatalytic, binding domains of PDEs. Even larger differences are seen between the requirements for binding to PDE catalytic sites and those for the cGMP- dependent protein kinase and the cGMP-gated cation channel.

Volume 47, Issue 2, pp. 330-339, 02/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. Surapisitchat, K.-I. Jeon, C. Yan, and J. A. Beavo Differential Regulation of Endothelial Cell Permeability by cGMP via Phosphodiesterases 2 and 3 Circ. Res., October 12, 2007; 101(8): 811 - 818. [Abstract] [Full Text] [PDF]

				H. Wang, Y. Liu, J. Hou, M. Zheng, H. Robinson, and H. Ke From the Cover: Structural insight into substrate specificity of phosphodiesterase 10 PNAS, April 3, 2007; 104(14): 5782 - 5787. [Abstract] [Full Text] [PDF]

				A. Boccaccio, L. Lagostena, V. Hagen, and A. Menini Fast Adaptation in Mouse Olfactory Sensory Neurons Does Not Require the Activity of Phosphodiesterase J. Gen. Physiol., July 31, 2006; 128(2): 171 - 184. [Abstract] [Full Text] [PDF]

				C. J. Busch, H. Liu, A. R. Graveline, and K. D. Bloch Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, April 1, 2006; 290(4): L747 - L753. [Abstract] [Full Text] [PDF]

				N. Herring, L. Rigg, D. A Terrar, and D. J Paterson NO-cGMP pathway increases the hyperpolarisation-activated current, If, and heart rate during adrenergic stimulation Cardiovasc Res, December 1, 2001; 52(3): 446 - 453. [Abstract] [Full Text] [PDF]

				S. B. Herman, D. M. Juilfs, E. B. Fauman, P. Juneau, and J. P. Menetski Analysis of a Mutation in Phosphodiesterase Type 4 that Alters Both Inhibitor Activity and Nucleotide Selectivity Mol. Pharmacol., May 1, 2000; 57(5): 991 - 999. [Abstract] [Full Text]

				M. Côté, M. D. Payet, E. Rousseau, G. Guillon, and N. Gallo-Payet Comparative Involvement of Cyclic Nucleotide Phosphodiesterases and Adenylyl Cyclase on Adrenocorticotropin-Induced Increase of Cyclic Adenosine Monophosphate in Rat and Human Glomerulosa Cells Endocrinology, August 1, 1999; 140(8): 3594 - 3601. [Abstract] [Full Text]

				L. Zhou, W. J. Thompson, and D. E. Potter Multiple Cyclic Nucleotide Phosphodiesterases in Human Trabecular Meshwork Cells Invest. Ophthalmol. Vis. Sci., July 1, 1999; 40(8): 1745 - 1752. [Abstract] [Full Text] [PDF]

				I. V. Turko, S. A. Ballard, S. H. Francis, and J. D. Corbin Inhibition of Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase (Type 5) by Sildenafil and Related Compounds Mol. Pharmacol., July 1, 1999; 56(1): 124 - 130. [Abstract] [Full Text]

				M. Kurjak, R. Fritsch, D. Saur, V. Schusdziarra, and H. D. Allescher NO releases bombesin-like immunoreactivity from enteric synaptosomes by cross-activation of protein kinase A Am J Physiol Gastrointest Liver Physiol, June 1, 1999; 276(6): G1521 - G1530. [Abstract] [Full Text] [PDF]

				I. V. Turko, S. H. Francis, and J. D. Corbin Potential Roles of Conserved Amino Acids in the Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5) J. Biol. Chem., March 13, 1998; 273(11): 6460 - 6466. [Abstract] [Full Text] [PDF]

				M. C. Hebert, F. Schwede, B. Jastorff, and R. H. Cote Structural Features of the Noncatalytic cGMP Binding Sites of Frog Photoreceptor Phosphodiesterase Using cGMP Analogs J. Biol. Chem., March 6, 1998; 273(10): 5557 - 5565. [Abstract] [Full Text] [PDF]

				A. E. Granovsky, M. Natochin, and N. O. Artemyev The gamma  Subunit of Rod cGMP-Phosphodiesterase Blocks the Enzyme Catalytic Site J. Biol. Chem., May 2, 1997; 272(18): 11686 - 11689. [Abstract] [Full Text] [PDF]

				E. Degerman, P. Belfrage, and V. C. Manganiello Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3) J. Biol. Chem., March 14, 1997; 272(11): 6823 - 6826. [Full Text] [PDF]

				I. V. Turko, T. L. Haik, L. M. McAllister-Lucas, F. Burns, S. H. Francis, and J. D. Corbin Identification of Key Amino Acids in a Conserved cGMP-binding Site of cGMP-binding Phosphodiesterases. A PUTATIVE NKXnD MOTIF FOR cGMP BINDING J. Biol. Chem., September 6, 1996; 271(36): 22240 - 22244. [Abstract] [Full Text] [PDF]